Exhibit 1.1 9,000,000 SHARES RIGEL PHARMACEUTICALS, INC. COMMON STOCK ($0.001 PAR VALUE) UNDERWRITING AGREEMENTUnderwriting Agreement • October 16th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • New York
X = Y (A-B) ------- ACommon Stock Purchase Warrant • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
RIGEL PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], TrusteeIndenture • March 9th, 2018 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
INDENTURE, dated as of [·], 20[·], among RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
16,000,000 Shares Rigel Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • April 20th, 2018 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
RIGEL PHARMACEUTICALS, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 18th, 2015 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
·], AS WARRANT AGENTPreferred Stock Warrant Agreement • March 9th, 2018 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
Exhibit 4.2 RIGEL PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT TABLE OF CONTENTSInvestor Rights Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
·], AS WARRANT AGENTCommon Stock Warrant Agreement • March 9th, 2018 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [·], between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 2nd, 2024 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
·], AS WARRANT AGENTWarrant Agreement • March 9th, 2018 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
This DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
RECITALSCollaboration Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
13,685,000 Shares Rigel Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 3rd, 2012 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
RIGEL PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20 RIGEL PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENTDebt Securities Warrant Agreement • May 7th, 2015 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
RECITALSIndemnification Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • Delaware
ARTICLE 1 DEFINITIONSTechnology Transfer Agreement • November 17th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
INDEMNITY AGREEMENTIndemnity Agreement • May 10th, 2007 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of __________ ___, 200__, is made by and between Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and _______________ (“Indemnitee”).
EXHIBIT 10.7 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("the Agreement") is entered into as of January 31, 1999 ("Effective Date") by and between PFIZER INC, a Delaware corporation, having an office...Collaborative Research and License Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • New York
EXHIBIT 10.3 RIGEL PHARMACEUTICALS, INC. 2000 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (INCENTIVE AND NONSTATUTORY STOCK OPTIONS) Pursuant to your Stock Option Grant Notice ("Grant Notice") and this Stock Option Agreement, RIGEL PHARMACEUTICALS,...Stock Option Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research
4. NET ISSUE ELECTION. The Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Preferred Stock equal to the value of this Warrant or any portion hereof by the surrender of this Warrant or such...Preferred Stock Purchase Warrant • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
CREDIT AND SECURITY AGREEMENT dated as of September 27, 2019 by and among RIGEL PHARMACEUTICALS, INC., as a Borrower and any additional borrower that hereafter becomes party hereto, and MIDCAP FINANCIAL TRUST, as Agent and as a Lender, and THE...Credit and Security Agreement • November 5th, 2019 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated as of September 27, 2019 (the “Closing Date”) by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust (“MidCap”), as administrative agent, the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), RIGEL PHARMACEUTICALS, INC., a Delaware corporation (“Rigel”), and the other entities from time to time party to this Agreement as borrowers (collectively in the singular, “Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay the Lenders. The parties agree as follows:
Exhibit 4.4 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY APPLICABLE STATE SECURITIES LAWS. AND MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE...Warrant Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
RECITALSLicense and Research Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
RIGEL PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENTPreferred Stock Warrant Agreement • January 8th, 2004 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
PREFERRED STOCK WARRANT AGREEMENT, dated as of between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the "COMPANY") and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the "WARRANT AGENT").
3,650,000 Shares Rigel Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2005 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
RIGEL PHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 1st, 2011 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Agreement”) is entered by and between Dr. Donald G. Payan (“Executive”) and RIGEL PHARMACEUTICALS, INC. (the “Company”), a Delaware corporation effective January 1, 2011 (the “Effective Date”). This Agreement shall replace and supersede that certain Employment Agreement between Executive and the Company entered into effective as of December 17, 2007, and amended and restated effective November 13, 2008 (the “Prior Agreement”).
3,165,000 Shares Rigel Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2004 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
September 26, 2016 Joe Lasaga [Address omitted] Re: Offer and Employment Terms Dear Joe:Employment Agreement • November 1st, 2016 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
Rigel Pharmaceuticals, Inc. (the Company) is pleased to offer you the position VP, Business Development and Alliance Management, reporting to me, Raul Rodriguez, on the following terms. Please take the next few days to carefully review the terms, and let us know if you have any questions.
RIGEL PHARMACEUTICALS, INC. AND STOCK OPTION AGREEMENT (INCENTIVE AND NONSTATUTORY STOCK OPTIONS)Stock Option Agreement • November 1st, 2011 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, RIGEL PHARMACEUTICALS, INC. (the “Company”) has granted you an option under its 2000 EQUITY INCENTIVE PLAN (the “2000 Plan”) or its 2011 EQUITY INCENTIVE PLAN (the “2011 Plan”), as identified on the Grant Notice (each to be referred to hereinafter, as applicable, as the “Plan”), to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Defined terms not explicitly defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan.
RIGEL PHARMACEUTICALS, INC., Issuer AND [·], Trustee INDENTURE Dated as of [·] Debt SecuritiesIndenture • December 14th, 2010 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS INDENTURE, dated as of [·], between RIGEL PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [·], as trustee (the “Trustee”):
13,000,000 Shares Rigel Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 17th, 2009 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
SECOND AMENDMENT TOCollaboration Agreement • November 13th, 2001 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to Collaboration Agreement (“Amendment”) is entered into as of July 6, 2001 (“Amendment Date”) by and between Rigel Pharmaceuticals, Inc., a Delaware corporation (“Rigel”) having offices at 240 East Grand Avenue, South San Francisco, CA 94080, and Novartis Pharma AG, a Swiss corporation (“Novartis”) having offices at Lichtstrasse 35, CH-4058, Basel, Switzerland. Rigel and Novartis are referred to herein collectively as the “Parties,” and each individually as a “Party.”
COLLABORATION AGREEMENTCollaboration Agreement • November 14th, 2002 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
RECITALSCollaborative Research and Development Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
RIGEL PHARMACEUTICALS 24 WINDSOR DRIVE, HILLSBOROUGH. CA 94010 PHONE/FAX: 415-579-4638Employment Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
Rigel Pharmaceuticals, Inc. (the "Company") is pleased to offer you the position of Vice President Research and Chief Operating Officer of the Company beginning January 16, 1997 ("Effective Date") on the terms set forth below (the "Agreement").
RIGEL PHARMACEUTICALS, INC. SECOND INVESTOR RIGHTS AGREEMENT June 26, 2003Investor Rights Agreement • March 12th, 2004 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
This Second Investor Rights Agreement (the “Agreement”) is entered into as of June 26, 2003 by and among Rigel Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
